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 PURPOSE: To define a minimum set of outcome mea-
sures for tracking, comparing, and improving macular
degeneration care.
 DESIGN: Recommendations from a working group of
international experts in macular degeneration outcomes
registry development and patient advocates, facilitated
by the International Consortium for Health Outcomes
Measurement (ICHOM).
 METHODS: Modified Delphi technique, supported by
structured teleconferences, followed by online surveys
to drive consensus decisions. Potential outcomes were
identified through literature review of outcomes collected
in existing registries and reported in major clinical trials.
Outcomes were refined by the working group and selected
based on impact on patients, relationship to good clinical
care, and feasibility of measurement in routine clinical
practice.
 RESULTS: Standardized measurement of the following
outcomes is recommended: visual functioning and quality
of life (distance visual acuity, mobility and independence,
emotional well-being, reading and accessing informa-
tion); number of treatments; complications of treatment;
and disease control. Proposed data collection sources
include administrative data, clinical data during routine
clinical visits, and patient-reported sources annually.
Recording the following clinical characteristics is recom-
mended to enable risk adjustment: age; sex; ethnicity;
smoking status; baseline visual acuity in both eyes; type
of macular degeneration; presence of geographic atrophy,
subretinal fibrosis, or pigment epithelial detachment;
previous macular degeneration treatment; ocular
comorbidities.
 CONCLUSIONS: The recommendedminimum outcomes
and pragmatic reporting standards should enable stan-
dardized, meaningful assessments and comparisons of
macular degeneration treatment outcomes. Adoption
could accelerate global improvements in standardized
data gathering and reporting of patient-centered out-
comes. This can facilitate informed decisions by patients
and health care providers, plus allow long-term moni-
toring of aggregate data, ultimately improving under-
standing of disease progression and treatment
responses. (Am J Ophthalmol 2016;168:1–12.
Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).)
M
ACULARDEGENERATION IS A LEADINGCAUSEOF
irreversible vision loss, accounting for over 15%
of blindness in high-income countries, with the
burden of this disease expected to increase with aging
populations.1 Age-related macular degeneration (AMD)
is the most prominent macular degeneration in populations
of European descent. Even in Asian populations, who are
known to have a lower risk of AMD than people of
European descent, AMD is one of the leading causes of
blindness.2 Although non-neovascular AMD is much
more common, untreated neovascular AMD used to
frequently be responsible for severe vision loss. Less
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common types of neovascular macular degeneration
include those secondary to myopia, trauma, inflammation,
macular telangiectasia, and idiopathic causes, all of which,
when associated with choroidal neovascularization (CNV),
are broadly treated with a similar approach as that for
neovascular AMD. Intravitreal anti–vascular endothelial
growth factor (anti-VEGF) therapy has become the
established treatment of neovascular AMD over the last
decade, supported by evidence from pivotal randomized
clinical trials.3,4
Interventional clinical trials are designed to maximize
the likelihood of demonstrating a treatment effect and
therefore often use a study population that may be
significantly different from the general population of
patients with the disease in question.5 For these and other
reasons, including less frequent treatment and less regular
follow-up than is inherent in a clinical trial, outcomes
achieved in the pivotal trials are not always replicated in
routine clinical practice.6,7 Interventional clinical trials
also suffer from relatively small numbers of patients who
are treated and short duration of follow-up, with only 3
major prospective studies reporting data beyond 2 years
of treatment.8–10 This is particularly problematic with
macular degeneration being a lifelong disease, for which
the long-term outcomes, especially with treatment, are
less well understood.
Various regimens have been developed to address the
vast burden of treatment for neovascular macular
degeneration. Monthly dosing, which was initially
recommended,11 has been largely supplanted by treat-
and-extend12 or variable as-required (pro re nata) dosing.13
Decisions regarding initiating treatment and retreatment
vary internationally and according to reimbursement
schemes, but are generally governed by changes in visual
acuity and CNV activity as determined by the detection
of intraretinal and subretinal fluid using optical coherence
tomography (OCT).14 There is also increasing choice
in anti-VEGF agents (ranibizumab, bevacizumab,
aflibercept) and numerous potential treatments for non-
neovascular AMD, which are currently being evaluated
in clinical trials.15
The limitations of clinical trials, variation in treatment
approaches and therapies, and ever-growing financial
burden of providing long-term treatment despite uncer-
tain long-term gains indicate that the need for systematic
measurement of the outcomes of macular degeneration
treatment in routine clinical practice is greater than
ever. However, only a few care providers around the
world routinely record outcome data for the treatment
they give to patients for macular degeneration outside
of clinical trials. There are, however, emerging ‘‘regis-
tries’’—national or multinational data repositories that
assimilate clinical outcome data from large numbers of in-
dividual practices. These include the significant projects
originating in Sweden (The Swedish Macula Register),16
Australia (The Fight Retinal Blindness! Project),17 the
United Kingdom (The UK National Ophthalmology
Database),18 and the Czech Republic (The Amadeus Proj-
ect).19 The largest is the Luminous Project, which has
recently completed enrollment of 30 000 patients across
5 continents (including up to 10% of patients undergoing
intravitreal anti-VEGF treatment for diabetic macular
edema and retinal vein occlusion); however, this only in-
cludes patient receiving ranibizumab.20 In the United
States, the American Academy of Ophthalmology Intelli-
gent Research in Sight (IRIS) project, which was
launched in 2014, is the first comprehensive eye disease
clinical registry, with macular degeneration outcome
measures in development.
Although existing efforts to measure outcomes of
macular degeneration treatment from routine clinical
care are a good start, there is no agreed standard
approach, and therefore significant variation exists in
what outcomes are recorded as well as how they are
measured and reported. An overview of the frequency at
which main outcomes are currently being measured in
existing registries and major clinical trials is provided in
Figure 1. The figure shows that visual acuity and compli-
cations of treatment are commonly included. However,
long-term disease control and anatomic outcomes are
tracked in fewer than half of the registries and trials.
The absence of an agreed standard approach limits the
ability to perform direct comparisons of different services
that could lead to improved outcomes. Most importantly,
functional outcomes that are more meaningful to patients
may be underrepresented compared to clinical or
anatomic outcomes, which are easier to measure but
may bear less direct relevance to patients.
Standardized and patient-centered outcome
measurement is therefore crucial in order to direct
improvements by those providing treatment, promote
dissemination of best practices, and ultimately drive
competition around quality. Systematic studies of interven-
tions for other diseases in routine practice have exposed sig-
nificant variation in outcomes that appeared to be
dependent on differences in institutional methods, physi-
cian preference, or health care systems.21 Continued data
collection and outcome reporting has subsequently led to
clear improvements in these outcomes.22,23 For these
reasons, a Working Group came together, facilitated by
the International Consortium for Health Outcomes
Measurement (ICHOM, a nonprofit organization with
the purpose to transform health care systems worldwide
by measuring and reporting patient outcomes in a
standardized way), to develop an international,
standardized, core set of patient-centered outcomes mea-
sures, with common definitions for routine clinical data
collection in macular degeneration care. It is hoped that
the minimum set of outcomes that we propose will be
used as a common platform for routine clinical data collec-
tion by those providing care for patients with macular
degeneration.
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METHODS
THE ICHOM APPROACH TO DEFINING HEALTH OUTCOMES
for conditions involves forming an international working
group that follows a structured approach to compile the
key outcomes and clinical characteristics that are recom-
mended to be measured in routine clinical practice, called
the ‘‘Standard Set.’’ The work was supported by sponsorship
from a number of charitable health care organizations, but
has no financial support from any pharmaceutical or health
care technology organizations.
 INTERNATIONALWORKINGGROUP: ICHOMconvened
a working group of 18 members, representing 10 different
countries from 4 continents (Figure 2). The working group
consisted of leading experts in the fields of macular degen-
eration outcomes and health care registry development, as
well as patient advocates. The working group lead, Profes-
sor Mark Gillies, has previously led the development of the
collaborative Fight Retinal Blindness! (FRB!) Project,24
which is an efficient, web-based system to track outcomes
of patients receiving treatment for neovascular AMD in
clinical practice. A project leader from ICHOM (S.S.)
managed the project, and an ICHOM Research Fellow
(I.R.) supported the content development. The other oph-
thalmologists among the working group had experience in
leading the retinal services in internationally recognized
ophthalmic units and established clinical data registries
in North America, Europe, and Asia. The patient represen-
tatives had direct experience of treatment for macular
degeneration and were involved in national charitable or-
ganizations for macular disease, which gave them access to
the insight of thousands of other patients with macular
degeneration.
 DEVELOPMENT OF STANDARD SET: A modified Delphi
technique was used to develop these recommendations,
in which a sequence of rounds of discussion followed by
an electronic survey were used to arrive at a consensus
among the experts who had differing views and perspec-
tives. This enabled the input from participants to be gath-
ered without requiring them to work face-to-face to find
consensus.
Six teleconferences were used to discuss outcomes and
clinical characteristics for inclusion in the Standard Set.
The first teleconference focused on the scope and outcome
domains for the Standard Set, supported by a literature re-
view of existing registries and major clinical trials to pro-
duce a long list of outcome measures that were being
recorded at the time.
The long list of potential outcomes was refined through
consensus discussions steered by the working group lead in
FIGURE 1. Frequency of main outcomes measured in existing registries and major clinical trials. The registries included are
Amadeus Project, Fight Retinal Blindness! Project, Luminous Project, Swedish Macula Register, and United Kingdom National
Ophthalmology Database. The trials included are ANCHOR, CATT, IVAN, and MARINA.
VOL. 168 3STANDARDIZED PATIENT-CENTERED MACULAR DEGENERATION OUTCOMES
order to prioritize outcomes that (1) had direct impact on
patients; (2) were sensitive to good clinical care; and (3)
were feasible to measure in routine clinical practice.
Following the teleconference, members submitted their
feedback and final votes on the inclusion of each outcome
through electronic surveys. A 75% majority of initial votes
was used as the threshold for inclusion of the outcome, and
below 50% was the threshold for rejecting outcomes. In
cases where a particular outcome received votes for inclu-
sion between 50% and 75%, the contentious point was
revisited on the next call and survey. The second telecon-
ference covered the measurement and definition of the
selected outcomes.
A similar process was undertaken in teleconferences 3
and 4 to identify the clinical characteristics that are recom-
mended to be measured in order to risk-stratify patients in
subsequent analyses. The measurement and definition of
the selected clinical characteristics was also agreed upon.
Publication, adoption, and implementation strategies
were discussed in teleconferences 5 and 6. The final Stan-
dard Set was refined and approved unanimously by all
members of the working group.
RESULTS
A SUMMARY OF THE ICHOM MACULAR DEGENERATION
Standard Set is shown in Tables 1–3, with additional
details in the sections below. A data collection manual
that further describes each measure, its definition,
suggested reporting format, inclusion and exclusion
criteria, and potential data sources is freely available on
the ICHOM Website (http://www.ichom.org/medical-
conditions/macular-degeneration/).
 CONDITIONS AND TREATMENT APPROACHES
COVERED: The Standard Set was developed to include
the broad disease categories of macular degeneration and
their treatments that were deemed to be sufficiently
different to warrant separation, as listed in Table 1. Other
forms of non-neovascular macular degeneration were
excluded owing to the large variation in the pathogenesis,
prognosis, and treatment of such diseases, which would
therefore require measurement of different clinical charac-
teristics and outcomes.
 OUTCOMES RECOMMENDED IN THE INTERNATIONAL
CONSORTIUM FOR HEALTH OUTCOMES MEASUREMENT
MACULARDEGENERATIONSTANDARDSET: A large num-
ber of potential outcomes were considered by the working
group before agreement on the final minimum set of out-
comes that are recommended for the affected eye, as
detailed below. Further details of these potential outcomes,
including the final voting decisions and summary of the
working group discussions that led to a decision of inclusion
or exclusion of individual outcomes, are included in
Supplemental Table 1 (Supplemental Material available
at AJO.com).
Visual Functioning and Vision-related Quality-of-Life
Outcomes. Because improving or maintaining visual
FIGURE 2. The International Consortium for Health Outcomes Measurement (ICHOM) macular degeneration working group.
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function is the primary goal for most patients with macular
degeneration, it is clearly an essential component of any
outcome assessment. We recommend recording of distance
visual acuity (best of uncorrected, corrected using glasses or
contact lenses, or pinhole if required) in the affected eye at
each clinical visit. Results should preferably be measured
using a logarithm of the minimal angle of resolution
(logMAR) or ETDRS chart, although other measurement
systems may be used and subsequently converted to
logMAR visual acuity.
When analyzing distance visual acuity outcomes of
treated eyes, we recommend reporting the following data:
 Mean change in visual acuity from baseline
 Proportion of eyes gaining vision (>_5 logMAR letters)
 Proportion of eyes with stable vision (within 15 logMAR
letters of baseline)
 Proportion of eyes with visual acuity of <_0.3 logMAR
(20/40 Snellen)
 Proportion of eyes with visual acuity of >_1.0 logMAR
(20/200 Snellen)
Wechose to recommendmeasuringmeanchange in visual
acuity after starting treatment because it has become the pri-
mary outcome of phase III clinical trials for neovascular
AMD.4,6 However, observational studies have found that,
because of ceiling effects, this may skew results in favor of
services that detect the disease and start treatment late,
since eyes with worse vision have more to gain compared
with eyes starting with good vision, which may not
gain anything.20 For this reason we recommend that the
proportion of eyes with stable vision, good vision (>_20/40),
and poor vision (<_20/200) should also be measured.
There is mounting evidence that increases in objectively
measured distance visual acuity do not necessarily concur
with improved visual functioning for patients.25 Therefore,
to fully measure the impact of macular degeneration treat-
ment, it is important to also assess how the patient’s vision-
related quality of life has changed. The working group felt
that measures of visual function other than distance visual
acuity, such as near visual acuity and reading speed, were
important outcomes. However, rather than requiring these
to be captured as clinical data in a clinical setting, they
recommended them to be measured collectively via subjec-
tive patient reporting from real life via a patient-reported
outcome measure (PROM). The working group felt that
use of PROM data would provide a superior reflection of
the visual function of patients in the real world than clin-
ical measures such as contrast sensitivity and that PROM
data would be of use in directing treatment.
We evaluated a number of existing, validated PROMs
that are potentially suitable for assessment of visual func-
tion affected by macular degeneration. These included
the Daily Living Tasks Dependent on Vision (DLTV),
Impact of Vision Impairment (IVI), Macular Disease Qual-
ity of Life (MacDQoL), Metamorphopsia Questionnaire,
and the National Eye Institute Visual Functioning Ques-
tionnaire (NEI-VFQ), which have been recently reviewed
by Khadka and associates.26 The criteria that we used to
evaluate all the relevant PROMs consisted of the
following: (1) content of the PROM (based on domains
of visual function that the working group felt were most
important to patients with macular degeneration,
including work/hobby continuation, face recognition/so-
cial participation, driving/transport, reading, self-care, gen-
eral enjoyment of life, activities involving near vision,
activities involving distance vision, bodily symptoms/func-
tions); (2) quality of the PROM (psychometric properties,
content development, reliability, and validity specifically
for macular disease); and (3) practical aspects related to us-
ing the PROM (available languages, time taken to com-
plete, costs involved with using in routine clinical care).
Based on our extensive evaluation and discussions, we
recommend the use of the Impact of Vision Impairment
(IVI) questionnaire27 at baseline, prior to initiating treat-
ment and annually while under follow-up. The importance
of follow-up assessment is to quantify changes in response
to treatments and to allow comparison between different
care providers. Annual reassessment has been recommen-
ded to minimize data collection burden but enable mean-
ingful changes to be detected in a reasonable period of
time. The IVI has been validated specifically in patients
with AMD and found to have appropriate content develop-
ment and reliability, plus has undergone Rasch analysis.28
It also scores highly on its psychometric properties,
including unidimensionality within each domain and
high measurement precision.
TABLE 1. Conditions and Treatments Included in the
International Consortium for Health OutcomesMeasurement
Macular Degeneration Standard Set
Conditions
Included
Neovascular macular degeneration:
Neovascular AMD
Polypoidal choroidal vasculopathy
Myopic neovascular macular degeneration
Other forms of neovascularmacular degeneration
(includes post-traumatic, inflammatory,
idiopathic, macular telangiectasia type 2)
Non-neovascular AMD
Treatments
Included
Intravitreal anti-VEGF treatment
Intravitreal steroids
Photodynamic therapy
Thermal laser photocoagulation
Retinal radiation therapy
Transpupillary thermotherapy
Retinal surgical treatment
Other
AMD ¼ age-related macular degeneration; VEGF ¼ vascular
endothelial growth factor.
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In terms of content, the IVI consists of 28 items that
cover an appropriate and broad range of questions that
comprise 3 domains: ‘‘mobility and independence,’’
‘‘emotional well-being,’’ and ‘‘reading and accessing infor-
mation.’’ The questions assess bodily symptoms and func-
tions, visual tasks and activities (in particular, those
requiring near vision), social participation, and emotional
well-being, which were all felt to be true outcomes of
high importance and relevance for patients with macular
degeneration. We do recognize that other PROMs are
widely used and can provide valuable information; howev-
er, our decision to recommend the IVI was to ensure that all
these important patient needs can be captured.
In practical terms, the IVI is also free to use (for noncom-
mercial purposes) and takes approximately 15 minutes
to complete using paper, computer, or touch screen–adapt-
ed versions. A guide to scoring and analysis of the IVI
is included in the ICHOM Macular Degeneration
Standard Set Reference Guide (available at http://www.
ichom.org/medical-conditions/macular-degeneration/). It
TABLE 2. Summary of Outcomes Recommended in the International Consortium for Health Outcomes Measurement Macular
Degeneration Standard Set
Measure Details Timing Data Source
Visual functioning and vision-
related quality of life
Distance visual acuity Distance visual acuity (best
of uncorrected, corrected,
or pinhole) in the affected
eye. Change in distance
visual acuity should be
calculated from baseline
and previous visual acuity
assessments.
 Each clinical visit Clinical data
Mobility and independence Impact of Vision Impairment
questionnaire
 Baseline (prior to
treatment)
 Annually (while on
treatment)
Patient reported
Emotional well-being Impact of Vision Impairment
questionnaire
 Baseline (prior to
treatment)
 Annually (while on
treatment)
Patient reported
Reading and accessing
information
Impact of Vision Impairment
questionnaire
 Baseline (prior to
treatment)
 Annually (while on
treatment)
Patient reported
Disutility of care Number of treatments Documentation of individual
treatments received for
macular degeneration
(Table 1)
 Each clinical visit Clinical or
administrative
data
Complications of treatmenta Endophthalmitis: Severe
intraocular inflammation
within 3 months of last
intraocular treatment, due
to infectious or
noninfectious causes
 Each clinical visit Clinical data
Disease control Presence of fluid, edema, or
hemorrhagea
Presence of intraretinal or
subretinal fluid or
hemorrhage that is
attributable to activity of
the neovascular lesion as
determined by the treating
ophthalmologist. This
could be based on clinical
examination or imaging.
 Each clinical visit Clinical data
aOutcomes applicable to neovascular macular degeneration only.
6 AUGUST 2016AMERICAN JOURNAL OF OPHTHALMOLOGY
TABLE 3. Summary of Clinical Characteristics and Interventions Recommended in the International Consortium for Health Outcomes
Measurement Macular Degeneration Standard Set
Measure Details Timing Data Source
Patient demographics Age Age in years, calculated from
birth date at
commencement of therapy
 At baseline Clinical or patient
reported
Sex Sex at birth  At baseline Clinical or patient
reported
Ethnicity Asian, Black, Hispanic, white,
mixed, other
 At baseline Patient reported
Smoking status Smoking status (of cigarettes,
cigars, or tobacco)
 At baseline Patient reported
Baseline functional
status
Baseline visual acuity Distance visual acuity (best of
uncorrected, corrected
using glasses or contact
lenses, or pinhole) in the
affected eye
 At baseline Clinical data
Baseline visual acuity in the
fellow eye
Distance visual acuity (best of
uncorrected, corrected
using glasses or contact
lenses, or pinhole) in the
fellow eye
 At baseline Clinical data
Clinical status Type of macular degeneration Type of macular degeneration
as defined in Table 1
 At baseline
 Prompt at each clin-
ical visit to check for
change
Clinical data
Geographic atrophy Presence of geographic
atrophy anywhere in the
macular area that is not
contiguous with the main
lesion
 At baseline
 Prompt at each clin-
ical visit to check for
change
Clinical data
Subretinal fibrosis Presence of subretinal fibrosis
anywhere in the macular
area
 At baseline
 Prompt at each clin-
ical visit to check for
change
Clinical data
Pigment epithelial detachment Presence and type of pigment
epithelial detachment
anywhere in the macular
area
 At baseline
 Prompt at each clin-
ical visit to check for
change
Clinical data
Associated clinical
history
Previous macular
degeneration treatment
Previous macular
degeneration treatment in
affected eye (multiple
options possible)
 At baseline Clinical or
administrative data
Ocular comorbidities Ocular comorbidities including
retinal vascular disease,
other macular pathology,
glaucoma or optic
neuropathy, amblyopia, or
medial opacity in affected
eye (multiple options
possible)
 At baseline
 Prompt annually to
check for change
Clinical or
administrative data
Additional interventions
to be recorded
 Cataract surgery
 YAG laser capsulotomy
 Retinal laser (ie, for macular edema or diabetic retinopathy)
 Vitrectomy
 Corneal surgery (ie, graft, pterygium)
 Prompt at each clin-
ical visit to check if
any other interven-
tions have occurred
Clinical or
administrative data
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has validated translations from the original English version
into a number of languages including Chinese,29
German,30 Melanesian,31 Hindi, and Telugu.32 We recog-
nize that widespread adoption will also require additional
translations to ensure comparability across populations.
The developers of the IVI are willing to provide advice
on the process of translation and validation if needed.
Disutility of Care Outcomes. The burden of care to pa-
tients was deemed to be important to measure, as the
frequent and regular treatments could have a negative
impact on the lives of patients and of those who care for
them, in terms of time and money as well as emotionally.
It is also possible that the number of treatments received
may not be the same as the number that would be recom-
mended if the logistics of clinic capacity and frequent pa-
tient visits were not an issue or if there were no financial
constraints. We therefore recommend that each individual
treatment received for macular degeneration should be
recorded at each clinical visit.
Complications related to treatment received for macular
degeneration, although occurring infrequently, are of sig-
nificant concern to patients. The most serious complica-
tion of intravitreal injections is endophthalmitis. We
therefore recommend capturing the incidence of severe
intraocular inflammation within 3 months of the intraoc-
ular treatment due to infectious or noninfectious causes.
This outcome is applicable for all patients undergoing
treatment for neovascular macular degeneration.
Other complications of treatment, such as retinal
pigment epithelium tears and retinal detachment, were
considered by the working group. However, they were
rejected from this minimum outcome set on the basis
that these were idiosyncratic complications, with potential
variability in detection rates. Further information on the
rationale of the working group decisions is included in
Supplemental Table 1.
Disease Control Outcomes. Long-term control of disease
was judged to be both significant to patients and often a
reflection of the treatment provided. For all types of
neovascular macular degeneration, we recommend report-
ing at each clinical visit the presence of intraretinal or
subretinal fluid or hemorrhage that is attributable to activ-
ity of the neovascular lesion as determined by the treating
ophthalmologist (based on clinical examination or imag-
ing).
Clinical measures such as central retinal thickness or size
of lesion were not included because these were not felt to be
outcomes of treatment that were important to patients. A
summary of all the outcomes that are recommended to be
recorded is presented in Table 2.
 CLINICALCHARACTERISTICSAND INTERVENTIONS: In
order to make meaningful outcome comparisons between
patients, it is important to measure certain baseline and
follow-up characteristics to enable subsequent appropriate
risk adjustment. The full list of potential clinical character-
istics that were considered are provided in Supplemental
Table 2 (Supplemental Material available at AJO.com),
along with the final voting decisions of the working group
on inclusion or exclusion of individual clinical characteris-
tics. A number of clinical characteristics where there is
good evidence of their impact on clinical outcomes
following treatment for macular degeneration were
discussed and finally selected.33,34 These are summarized
in Table 3, grouped under the categories of patient demo-
graphics, baseline functional status, clinical status, and
associated clinical history. Systemic comorbidities such as
cerebrovascular and cardiovascular disease were not
included to minimize data collection burden. Similarly,
the suggested reporting format for these characteristics
and interventions has been simplified to facilitate data
collection while still providing useful information.
We also recommend recording of interventions to the
affected eye that are likely to have an impact on the out-
comes that are recommended to be collected, in particular
visual functioning and vision-related quality-of-life out-
comes. These are also listed in Table 3.
 DATA COLLECTION: The timeline for the suggested
recording of the different categories of outcomes and clin-
ical characteristics is summarized in Figure 3. We also sug-
gest prompts at each clinical visit to check if certain
clinical characteristics have changed and if any other rele-
vant interventions have occurred, as indicated in Table 3.
We envisage that this would be performed by some form of
electronic patient record and that the prompting, rather
than have more mandatory fields, would reduce data collec-
tion burden.
A very important long-term goal of ICHOM is to pro-
duce data that can be easily compared across providers,
centers, and countries. To achieve this, we recommend
processes to reduce variability, including the use of similar
data sources, recognizing that the specific details of data
collection will differ by center. As outlined in Tables 2
and 3, the potential sources are administrative data, clin-
ical data, and patient-reported sources. We recommend
that the source of data, as well as the response rate (if pa-
tient reported), be tracked for every measure. In the face
of regulatory, privacy, and information technology chal-
lenges, we advocate that centers without a national registry
track these data individually with the anticipation that
future efforts led by ICHOM will facilitate standardized
comparisons among centers.
DISCUSSION
THE ICHOM MACULAR DEGENERATION WORKING GROUP
set out to develop a minimum set of standardized
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patient-centered outcome measures for macular degenera-
tion that are practical for all health care providers to record
in routine clinical practice. Additional clinical characteristics
are also suggested to ensure that it will be possible to
perform case-mix risk-adjusted analysis. Although there
are a number of existing projects where data on macular
degeneration outcomes are routinely collected, our
research showed that there are significant differences
both in the outcomes that are collected and in the way
they are measured. Defining a standardized set of minimum
outcomes will therefore enable meaningful results for
health care professionals to objectively assess their perfor-
mance and drive improvements in their clinical practice.
It will also allow for insurers or commissioners to under-
stand the quality and value of care that is being funded,
and—importantly—for patients to make well-informed de-
cisions about their treatment.
According to the disease model suggested by Porter,35 vi-
sual function in real-life situations, the burden and compli-
cations of receiving treatment, and long-term disease
control and quality of life are likely to be of most signifi-
cance to patients. On the other hand, change in central
macular thickness or the size of the lesion have less direct
impact on patients, yet are often reported and discussed.
The macular degeneration outcome set that we developed
includes a PROM. Although PROMs are used much less
often than measurements of visual acuity, implementing
regular PROM measurement as part of routine clinical
ophthalmology practices is possible.36
Of course, measures included in the Standard Set reflect
a balance between meaningful and pragmatic data collec-
tion that can be incorporated into existing patient path-
ways internationally, and in a variety of clinical contexts.
The resultant minimum core dataset is therefore inevitably
a compromise between intricate details that may be useful
for comparison and the practicalities and burden of data
collection. Interested care providers should therefore add
additional outcomes to meet their specific requirements.
Implementation of the ICHOM macular degeneration
Standard Set to collect data from routine clinical care
FIGURE 3. Time points for the suggested recording of outcomes and baseline characteristics in the International Consortium for
Health Outcomes Measurement macular degeneration Standard Set.
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remains a key challenge for the future. The working group
has a wealth of experience in outcomes data measurement
and has designed this minimum dataset to be realistic to
capture in most settings. The majority of the data is already
measured in routine clinical practice, although not
currently in a standardized manner. Furthermore, there
are already existing projects that have produced numerous
publications, including those by Gillies and associates24
and Johnston and associates,37 that use outcome data
captured during routine clinical practice. The one excep-
tion to this is the PROM. However, the working group,
particularly with the contribution of its patient
representatives, believes that these patient-reported out-
comes are as vital as any of the clinical outcomes. This is
because only the patient-reported outcomes can truly
reflect how a treatment actually affects patients. Further-
more, PROMs have demonstrated clinically relevant im-
provements in patient-reported visual functioning in
randomized clinical trials of intravitreal therapy for neovas-
cular macular degeneration regardless of whether the
treated eye is the better- or worse-seeing eye at onset of
treatment.38
We do also recognize that in many countries, significant
financial and logistical challenges to collecting outcomes
remain in terms of both clinical and patient-reported
data. However, with future development in health infor-
mation technology it is likely that these barriers will
become less significant over time. ICHOM will continue
to work with organizations around the world to encourage
adoption of the macular degeneration Standard Set and is
planning to facilitate global comparisons between provider
organizations as adoption takes place.
We acknowledge that this work does have limitations.
The proposed minimum dataset has not been widely
consulted on and has been derived from consensus opin-
ions. However, the working group has made these recom-
mendations based on the best currently available relevant
evidence and an enormous collective wealth of experience.
Secondly, the dataset has not been piloted, and although
we do not envisage problems with the feasibility of the clin-
ical data collection (as the vast majority of the outcomes
and baseline characteristics that are recommended have
individually been used successfully in other registries and
clinical trials), measurement of the PROM data may be a
barrier to implementation, as this is not currently measured
routinely. We anticipate that participation in data collec-
tion and feedback will inform future iterations of the Stan-
dard Set, and a steering committee will also be formed from
the existing working group to review and, if necessary, up-
date the recommendations on an annual basis, to ensure
that it remains current and relevant for both patients and
physicians with the developments in the evidence base
and macular degeneration treatment.
We acknowledge that randomized studies remain the
gold standard for outcome comparisons between
treatments, but we believe that registries serve as essential
companion efforts to assess the effectiveness of treatments
in real-world settings. Nevertheless, the current work is
also limited by the fact that the utility of this proposed
minimum dataset is currently undetermined. It is likely,
however, that collecting and reporting these data will
lead to better understanding of the health benefits and
prognosis for real-life clinical scenarios, as has been
demonstrated in other areas of medicine and subsequent
improvements in outcomes. This will be especially
relevant for patients with multiple comorbidities who
would usually be excluded from randomized clinical trials.
The usefulness of the data will, however, be limited by the
honesty in which it is collected the accuracy with which
it is recorded and the transparency in which it is shared. It
is important that this is emphasized, especially when out-
comes are increasingly being linked to reimbursement.
High volumes of good-quality data from routine clinical
practice can rapidly be achieved through systematic data
collection of standardized outcomes. This provides new
information that can enable better decision making about
how, when, and where to treat patients with different
clinical characteristics. It may shed light on the as-yet-
unanswered and ever-growing questions in macular degen-
eration, including the optimal criteria for treatment, which
treatment or combination of treatments, or which follow-
up and retreatment regimen leads to the best outcomes
that matter most to patients.
The United Kingdom Cataract National Dataset is an
example in ophthalmology of how pooled data, collected
as part of routine clinical care via electronic patient record
systems, has provided valuable benchmarking standards
that have later led to improvements in risk profiling of pa-
tients.39 To help similar projects globally collect data in a
standardized and therefore comparable manner, ICHOM
has recently published a proposed minimum set of outcome
measures for cataract surgery.40
We hope our recommendations will facilitate and accel-
erate global improvements in the outcomes of treatment of
macular degeneration, by encouraging wider collaborative
and consistent measurement of meaningful outcomes by
care providers and enabling comparison between different
care providers and different countries.
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